posted
I don't know about Quest, but I am continuing to buy. Trying to get more under $0.045. Hopefully $0.04 before the MMs run it.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes.
IP: Logged |
posted
CalbaTech Highlights Positive Report in Cell Online Magazine - Research Provides New Data That Further Supports Adult Stem Cell Banking Service IRVINE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on providing products and platforms to the biotech and pharmaceutical research market and to academic institutions, and banking of adult stem cells for possible future therapeutic uses, today announced that a recent research report provides new data that initially suggests that cells collected during the Stem Cell MicroBank(TM) Service can be manipulated to mirror embryonic stem cells. The link to the article is http://www.cell.com/content/article/fulltext?uid=PIIS0092867406009767.
Much of the controversy surrounding embryonic stem cells centers on the destruction of the embryo caused during the harvesting of the stem cells. Researchers have largely focused their attention on embryonic stem cells due to the cell's plasticity or the ability of stem cells to differentiate into specialized cells of another tissue type. Advancements in therapies to date have been made because of the amount of resources provided to embryonic stem cell research.
This report, however, may signal a shift in focus by researchers as the plasticity in adult stem cells is better understood. Using autologous stem cells at the time of transplantation might also overcome a major unknown hurdle related to embryonic stem cells, that being possible tissue rejection. Proponents of embryonic stem cell research rarely discuss this potential limitation, while the transplantation of autologous adult stem cells should not result in tissue rejection.
CalbaTech's wholly-owned subsidiary, LifeStem has created a multi-tissue, autologous adult stem cell banking service that allows adults to bank their own stem cells for possible future therapeutic use.
LifeStem's Chief Medical Officer, Dr. Jason R. Van Tassel noted that in this study, the cells were generated from adult cultured fibroblasts under specific conditions whereby the cells were grown in the presence of several transcription factors expressed by embryonic stem cells. These cells were then implanted into both mouse embryos and adult mice and differentiated into the three cell lineages seen in early development. This could be the 'holy grail' for autologous banking of adult stem cells.
'Further in-vitro directed differentiation of these induced stem cells to specific cell types could provide a limitless source of a variety differentiated cells for numerous human therapeutic applications. We are entirely encouraged by this new data and we believe that it brings new concrete evidence that autologous adult stem cell banking is the proper strategy for patients to benefit from this emerging field,' said Dr. Van Tassel. The study did show, however, that when these induced stem cells were transplanted into adult mice, several mice developed tumors. Dr. Van Tassel continued, 'This is to be expected in a preliminary study where such highly undifferentiated cells were implanted. Furthermore, subsequent differentiation of these populations should eliminate the risk of malignancy in therapeutic applications.'
LifeStem, Inc. has launched its Stem Cell MicroBank(TM) Service in California and expects to add Florida, New York, North Carolina and other states in the very near future. LifeStem is projecting $3.9 million in revenues in the first twelve months of operating the nation's first service to collect micro-quantities of adult stem cells from multiple tissue sources for future potential therapeutic use.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain 'forward-looking' information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. We use words such as 'anticipate,' 'believe,' 'expect,' 'future,' 'intend,' 'plan,' and similar expressions to identify forward-looking statements. These statements including those related to being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on Form 10-KSB, and Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
quote:Originally posted by insuranceman: Why would they do that when they had thier chance with all the PR recently.
Review IGAI's 1300% run. Psychologically a PR comes out, everyone assumes it will run. So the MMs actually lower the PPs, people bail, MMs collect cheap shares, then they run it when they are ready. They, of course win.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes.
IP: Logged |
quote:Originally posted by insuranceman: ...which would be bad in the long run.
These are penny stocks, never care about the long run. Use them, get your profit and get out.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
